Clinical Trials Logo

Essential Hypertension clinical trials

View clinical trials related to Essential Hypertension.

Filter by:

NCT ID: NCT02277691 Completed - Clinical trials for Essential Hypertension

A Phase III Long-term Study of TAK-536TCH in Patients With Essential Hypertension

Start date: November 2014
Phase: Phase 3
Study type: Interventional

Primary objective of this study is to evaluate the safety of long-term administration of TAK-536, amlodipine (AML), and hydrochlorothiazide (HCTZ) in patients with essential hypertension.

NCT ID: NCT02194465 Completed - Clinical trials for Primary Hypertension

A Study of LY2623091 in Participants With High Blood Pressure

Start date: August 2014
Phase: Phase 2
Study type: Interventional

The main purpose of this study is to evaluate the safety and effectiveness of the study drug known as LY2623091 in participants with high blood pressure.

NCT ID: NCT02152306 Completed - Clinical trials for Essential Hypertension

Fimasartan/Amlodipine Combination Phase III

Start date: April 2014
Phase: Phase 3
Study type: Interventional

The aim of this study is to ensure the superiority of Fimasartan/Amlodipine combination in hypotensive effect after 8 weeks of treatment over Fimasartan monotherapy in patients with hypertension who have no response to Fimasartan 60mg monotherapy.

NCT ID: NCT02062645 Completed - Clinical trials for Essential Hypertension

Study of Efficacy and Safety of CVAA489 in Hypertensive Patients

Start date: February 2014
Phase: Phase 4
Study type: Interventional

The population that will be included in this study, will be regular Turkish hypertensive patients who are expected to consume sodium in high amounts. It is hypothesized that, in that population, amlodipine/valsartan will be effective at the same rate of blood pressure (BP) control rate as expected from literature.

NCT ID: NCT02058446 Completed - Clinical trials for Essential Hypertension

PMS Study of Amlodipine/Valsartan for the Treatment of Hypertension

Start date: October 2013
Phase: Phase 4
Study type: Interventional

The antihypertensive effect of Amlodipine/Valsartan combination has been evaluated in worldwide populations including Asian patients. The study primarily aims to evaluate the effectiveness of Amlodipine/Valsartan combination in patients with essential hypertension in Taiwan using a prospective, open-label, non-randomized approach. The study also wants to investigate the safety of Amlodipine/Valsartan combination during the 6-week treatment period.

NCT ID: NCT02031861 Completed - Clinical trials for Essential Hypertension

Efficacy Study of Nifedipine Controlled-Release Tablets (Xin Ran) to Treat Mild to Moderate Essential Hypertension

Start date: February 2014
Phase: Phase 4
Study type: Interventional

The purpose of this study is to compare nifedipine controlled-release (CR) tablets (Xin Ran) with nifedipine controlled-release tablets (Adalat)in the treatment of mild to moderate essential hypertension.

NCT ID: NCT01900184 Completed - Clinical trials for Essential Hypertension

Study of the Product QGC001 as a Single Dose and Multiple Doses Administered Orally to Healthy Adult Subjects

Start date: December 2012
Phase: Phase 1
Study type: Interventional

1QG2 is a Phase 1 study aiming to assess the safety and tolerability of ascending single/multiple oral doses (SAD & MAD) in healthy young subjects, the preliminary food interaction and the effect of QGC001 on blood pressure and heart rate, but also to determine pharmacokinetic preliminary profiles of QGC001 and its metabolite EC33 and pharmacodynamic preliminary profiles of QGC001 and its metabolite EC33 especially effects on the renin-angiotensin-aldosterone and copeptin systems.

NCT ID: NCT01900171 Completed - Clinical trials for Essential Hypertension

Phase I Study in Healthy Male Subjects Comparing QGC001 to Placebo

Start date: February 2012
Phase: Phase 1
Study type: Interventional

QGC001/1QG1 is a Phase I "first time in man" study aiming to determine the overall safety and tolerability of single ascending oral doses of QGC001 in healthy male subjects compared to placebo, as well as the pharmacokinetics of QGC001 and its metabolite EC33 and the pharmacodynamic properties of QGC001 (effects on the renin-angiotensin-aldosterone system, blood pressure and heart rate) in healthy male subjects.

NCT ID: NCT01878201 Completed - Clinical trials for Essential Hypertension

A Valsartan 80 Mg-Referenced, Therapeutic Exploratory Clinical Study to Evaluate the Antihypertensive Efficacy of Fimasartan 30 mg During 24 Hours in Patients With Mild to Moderate Essential Hypertension

Start date: May 2013
Phase: Phase 2
Study type: Interventional

The purpose of this study is to Evaluate the Antihypertensive efficacy of Fimasartan 30 mg during 24 hours in Patients with Mild to Moderate Essential Hypertension

NCT ID: NCT01873885 Completed - Clinical trials for Essential Hypertension

Phase 1, Randomized, Double-Blind, Placebo-Controlled Exploratory Study That Will Assess the Safety, Tolerability, Pharmacokinetics and Hemodynamic Response to a Single 30 Minute Intravenous Infusion of Vasomera™ (PB1046) in Adult Subjects With Stage 1 or 2 Essential Hypertension

Start date: June 2013
Phase: Phase 1
Study type: Interventional

This study is an exploratory Phase 1 randomized, double-blind (Investigator and study subject and 2-D echo endpoint assessor), placebo-controlled single IV infusion dose escalation study that will enroll up to approximately 32 subjects with stage 1 or 2 essential hypertension.